Wuxi Biologics

Wuxi Biologics: Emissions Overview and Climate Commitments

Wuxi Biologics, headquartered in China and operating within the Research and Development in Biotechnology (except Nanobiotechnology) sector, has reported significant progress in its climate action.

Emissions Data:

For the fiscal year 2025, Wuxi Biologics reported a total of approximately 230 million kg CO2e in Scope 1 and 2 emissions. Breaking this down further:

• Scope 1 emissions: Approximately 44.1 million kg CO2e.
• Scope 2 emissions: Approximately 185.6 million kg CO2e.

In 2024, the company's Scope 1 and 2 emissions totalled approximately 198.7 million kg CO2e, with Scope 1 emissions at about 38.3 million kg CO2e and Scope 2 emissions at approximately 160.3 million kg CO2e.

Prior to this, in 2023, Wuxi Biologics' Scope 1 and 2 emissions were approximately 181.9 million kg CO2e, comprising around 32.7 million kg CO2e from Scope 1 and roughly 149.2 million kg CO2e from Scope 2.

For 2022, the company's Scope 1 and 2 emissions amounted to approximately 169.8 million kg CO2e, with Scope 1 at about 33.8 million kg CO2e and Scope 2 at approximately 136.1 million kg CO2e.

In 2021, Wuxi Biologics reported Scope 1 and 2 emissions of approximately 144.2 million kg CO2e, consisting of roughly 29.9 million kg CO2e in Scope 1 and about 114.3 million kg CO2e in Scope 2.

In 2020, the company's Scope 1 and 2 emissions were approximately 85.4 million kg CO2e, with Scope 1 at around 11.0 million kg CO2e and Scope 2 at approximately 74.4 million kg CO2e.

For 2019, Wuxi Biologics reported Scope 1 and 2 emissions totalling approximately 78.9 million kg CO2e, with Scope 1 at about 10.6 million kg CO2e and Scope 2 at approximately 68.3 million kg CO2e.

In 2018, the company's Scope 1 and 2 emissions were approximately 54.3 million kg CO2e, comprising around 4.2 million kg CO2e from Scope 1 and approximately 50.1 million kg CO2e from Scope 2.

While Scope 3 data is increasingly being disclosed, specific total figures for Scope 3 emissions across all categories are not fully detailed for all reported years. For 2025, some Scope 3 categories reported include business travel (approximately 3.9 million kg CO2e), employee commute (approximately 22.5 million kg CO2e), and waste generated in operations (approximately 5.9 million kg CO2e).

Climate Commitments and Reduction Targets:

Wuxi Biologics has set ambitious climate targets aligned with a 1.5°C pathway. Key commitments include:

• Net-Zero Goal: The company commits to achieving net-zero greenhouse gas emissions across its value chain by 2050.
• Near-Term Absolute Reductions: Wuxi Biologics aims to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 58.8% by 2034, using 2024 as the base year.
• Long-Term Absolute Reductions: The company targets a 90% reduction in absolute Scope 1 and 2 GHG emissions by 2050, also from a 2024 baseline.
• Scope 3 Reduction: Wuxi Biologics is committed to reducing Scope 3 GHG emissions, specifically for purchased goods and services, by 63.8% per kg of product produced by 2034. Furthermore, there is a commitment to reduce absolute Scope 3 emissions (covering purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, and employee commuting) by 90% by 2050.
• Intensity Reduction (Mid-term): Previously, the company had a mid-term goal to reduce its Scope 1 and 2 GHG emission intensity by 50% (tonnes/RMB10,000) by 2030, based on a 2020 baseline.

These commitments are publicly available through their Science Based Targets initiative (SBTi) disclosures, demonstrating a clear strategy to decarbonise their operations and value chain.